VERONA PHARMA LIMITED

05375156
Active United Kingdom

Research and experimental development on biotechnology

209 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
V

VERONA PHARMA LIMITED

05375156

Research and experimental development on biotechnology

Founded 24 Feb 2005 Active United Kingdom 209 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

VERONA PHARMA PLC. 18 Sept 2006 — 22 Oct 2025
ISIS RESOURCES PLC 24 Feb 2005 — 18 Sept 2006
VERONA PHARMA LIMITED. 22 Oct 2025 — 31 Dec 1999
Accounts Due 30 Sept 2026 3 months remaining
Confirmation Submitted 15 May 2026 Next due 10 Mar 2027 8 months remaining
Net assets £163M £33M 2024 year on year
Total assets £378M £136M 2024 year on year
Total Liabilities £215M £169M 2024 year on year
Charges 13
4 outstanding 9 satisfied

Contact & Details

Contact

Email

info@example.com

Website

www.example.com

Full company profile for VERONA PHARMA LIMITED (05375156), an active life sciences and medical technology company based in United Kingdom. Incorporated 24 Feb 2005. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type group
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2013–2024)

Cash in Bank

£318.65M

Increased by £105.25M (+49%)

Net Assets

£163.05M

Decreased by £32.68M (-17%)

Total Liabilities

£214.96M

Increased by £168.76M (+365%)

Turnover

£33.70M

Employees

209

Increased by 130 (+165%)

Debt Ratio

57%

Increased by 38 (+200%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 6

Investors (23)

Investor NameInvestor SinceParticipating Rounds
Investor 20Feb 2012Series A
Investor 1Jun 2016Series C, Private Equity, IPO
Investor 2Jun 2016Series C, Private Equity, IPO

Share Capital

Share Capital

Share allotments and capital structure

74 Allotments 2,811,396,087 Shares £337.34m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
16 Dec 202415,200,000£760k£0.05
2 Dec 2024356,040£1.38m£3.862
2 Dec 2024162,312£638k£3.93
2 Dec 20247,780,016£30.08m£3.866
2 Dec 2024323,152£1.28m£3.958

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (61)

Ra Capital Management, Limited Partnership
8.9%
Ra Capital Heatlhcare Fund Lp
6.8%

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Merck & Co., Inc

Unknown

Active
Notified 7 Oct 2025
Nature of Control
  • Ownership Of Shares 75 To 100 Percent
  • Voting Rights 75 To 100 Percent
  • Right To Appoint And Remove Directors

Group Structure

Group Structure

VERONA PHARMA LIMITED Current Company

Charges

Charges

4 outstanding 9 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
29 May 2026OfficersTermination of Ben Harber as director on 23 May 2026
27 May 2026ResolutionResolutions
27 May 2026IncorporationMemorandum Articles
24 May 2026CapitalCapital Name Of Class Of Shares
22 May 2026CapitalCapital Variation Of Rights Attached To Shares
29 May 2026 Officers

Termination of Ben Harber as director on 23 May 2026

27 May 2026 Resolution

Resolutions

27 May 2026 Incorporation

Memorandum Articles

24 May 2026 Capital

Capital Name Of Class Of Shares

22 May 2026 Capital

Capital Variation Of Rights Attached To Shares

Recent Activity

Latest Activity

Termination of Ben Harber as director on 23 May 2026

4 weeks ago on 29 May 2026

Resolutions

1 months ago on 27 May 2026

Memorandum Articles

1 months ago on 27 May 2026

Capital Name Of Class Of Shares

1 months ago on 24 May 2026

Capital Variation Of Rights Attached To Shares

1 months ago on 22 May 2026